Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal?
Identifieur interne : 000848 ( PubMed/Corpus ); précédent : 000847; suivant : 000849Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal?
Auteurs : Ronald B. Postuma ; Jean-Francois Gagnon ; Maria Tuineaig ; Josie-Anne Bertrand ; Veronique Latreille ; Catherine Desjardins ; Jacques Y. MontplaisirSource :
- Sleep [ 1550-9109 ] ; 2013.
English descriptors
- KwdEn :
- Aged, Antidepressive Agents (adverse effects), Case-Control Studies, Color Perception (drug effects), Humans, Male, Middle Aged, Neurodegenerative Diseases (chemically induced), Neurodegenerative Diseases (diagnosis), Parkinson Disease, Secondary (diagnosis), Parkinson Disease, Secondary (etiology), Prodromal Symptoms, Prospective Studies, REM Sleep Behavior Disorder (chemically induced), Risk Factors, Smell (drug effects).
- MESH :
- chemical , adverse effects : Antidepressive Agents.
- chemically induced : Neurodegenerative Diseases, REM Sleep Behavior Disorder.
- diagnosis : Neurodegenerative Diseases, Parkinson Disease, Secondary.
- drug effects : Color Perception, Smell.
- etiology : Parkinson Disease, Secondary.
- Aged, Case-Control Studies, Humans, Male, Middle Aged, Prodromal Symptoms, Prospective Studies, Risk Factors.
Abstract
Antidepressants, among the most commonly prescribed medications, trigger symptoms of REM sleep behavior disorder (RBD) in up to 6% of users. Idiopathic RBD is a very strong prodromal marker of Parkinson disease and other synuclein-mediated neurodegenerative syndromes. It is therefore critically important to understand whether antidepressant-associated RBD is an independent pharmacologic syndrome or a sign of possible prodromal neurodegeneration.
DOI: 10.5665/sleep.3102
PubMed: 24179289
Links to Exploration step
pubmed:24179289Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal?</title><author><name sortKey="Postuma, Ronald B" sort="Postuma, Ronald B" uniqKey="Postuma R" first="Ronald B" last="Postuma">Ronald B. Postuma</name><affiliation><nlm:affiliation>Department of Neurology, McGill University, Montreal General Hospital, Montreal, Québec, Canada ; Centre d'Études Avancées en Médecine du Sommeil, Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Gagnon, Jean Francois" sort="Gagnon, Jean Francois" uniqKey="Gagnon J" first="Jean-Francois" last="Gagnon">Jean-Francois Gagnon</name></author><author><name sortKey="Tuineaig, Maria" sort="Tuineaig, Maria" uniqKey="Tuineaig M" first="Maria" last="Tuineaig">Maria Tuineaig</name></author><author><name sortKey="Bertrand, Josie Anne" sort="Bertrand, Josie Anne" uniqKey="Bertrand J" first="Josie-Anne" last="Bertrand">Josie-Anne Bertrand</name></author><author><name sortKey="Latreille, Veronique" sort="Latreille, Veronique" uniqKey="Latreille V" first="Veronique" last="Latreille">Veronique Latreille</name></author><author><name sortKey="Desjardins, Catherine" sort="Desjardins, Catherine" uniqKey="Desjardins C" first="Catherine" last="Desjardins">Catherine Desjardins</name></author><author><name sortKey="Montplaisir, Jacques Y" sort="Montplaisir, Jacques Y" uniqKey="Montplaisir J" first="Jacques Y" last="Montplaisir">Jacques Y. Montplaisir</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:24179289</idno><idno type="pmid">24179289</idno><idno type="doi">10.5665/sleep.3102</idno><idno type="wicri:Area/PubMed/Corpus">000848</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000848</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal?</title><author><name sortKey="Postuma, Ronald B" sort="Postuma, Ronald B" uniqKey="Postuma R" first="Ronald B" last="Postuma">Ronald B. Postuma</name><affiliation><nlm:affiliation>Department of Neurology, McGill University, Montreal General Hospital, Montreal, Québec, Canada ; Centre d'Études Avancées en Médecine du Sommeil, Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Gagnon, Jean Francois" sort="Gagnon, Jean Francois" uniqKey="Gagnon J" first="Jean-Francois" last="Gagnon">Jean-Francois Gagnon</name></author><author><name sortKey="Tuineaig, Maria" sort="Tuineaig, Maria" uniqKey="Tuineaig M" first="Maria" last="Tuineaig">Maria Tuineaig</name></author><author><name sortKey="Bertrand, Josie Anne" sort="Bertrand, Josie Anne" uniqKey="Bertrand J" first="Josie-Anne" last="Bertrand">Josie-Anne Bertrand</name></author><author><name sortKey="Latreille, Veronique" sort="Latreille, Veronique" uniqKey="Latreille V" first="Veronique" last="Latreille">Veronique Latreille</name></author><author><name sortKey="Desjardins, Catherine" sort="Desjardins, Catherine" uniqKey="Desjardins C" first="Catherine" last="Desjardins">Catherine Desjardins</name></author><author><name sortKey="Montplaisir, Jacques Y" sort="Montplaisir, Jacques Y" uniqKey="Montplaisir J" first="Jacques Y" last="Montplaisir">Jacques Y. Montplaisir</name></author></analytic><series><title level="j">Sleep</title><idno type="eISSN">1550-9109</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antidepressive Agents (adverse effects)</term><term>Case-Control Studies</term><term>Color Perception (drug effects)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neurodegenerative Diseases (chemically induced)</term><term>Neurodegenerative Diseases (diagnosis)</term><term>Parkinson Disease, Secondary (diagnosis)</term><term>Parkinson Disease, Secondary (etiology)</term><term>Prodromal Symptoms</term><term>Prospective Studies</term><term>REM Sleep Behavior Disorder (chemically induced)</term><term>Risk Factors</term><term>Smell (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antidepressive Agents</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Neurodegenerative Diseases</term><term>REM Sleep Behavior Disorder</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Neurodegenerative Diseases</term><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Color Perception</term><term>Smell</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Case-Control Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prodromal Symptoms</term><term>Prospective Studies</term><term>Risk Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Antidepressants, among the most commonly prescribed medications, trigger symptoms of REM sleep behavior disorder (RBD) in up to 6% of users. Idiopathic RBD is a very strong prodromal marker of Parkinson disease and other synuclein-mediated neurodegenerative syndromes. It is therefore critically important to understand whether antidepressant-associated RBD is an independent pharmacologic syndrome or a sign of possible prodromal neurodegeneration.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24179289</PMID><DateCreated><Year>2013</Year><Month>11</Month><Day>01</Day></DateCreated><DateCompleted><Year>2014</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2015</Year><Month>04</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1550-9109</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>11</Issue><PubDate><Year>2013</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Sleep</Title><ISOAbbreviation>Sleep</ISOAbbreviation></Journal><ArticleTitle>Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal?</ArticleTitle><Pagination><MedlinePgn>1579-85</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5665/sleep.3102</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Antidepressants, among the most commonly prescribed medications, trigger symptoms of REM sleep behavior disorder (RBD) in up to 6% of users. Idiopathic RBD is a very strong prodromal marker of Parkinson disease and other synuclein-mediated neurodegenerative syndromes. It is therefore critically important to understand whether antidepressant-associated RBD is an independent pharmacologic syndrome or a sign of possible prodromal neurodegeneration.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Tertiary sleep disorders center.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">100 patients with idiopathic RBD, all with diagnosis confirmed on polysomnography, stratified to baseline antidepressant use, with 45 matched controls.</AbstractText><AbstractText Label="MEASUREMENTS/RESULTS" NlmCategory="RESULTS">Of 100 patients, 27 were taking antidepressants. Compared to matched controls, RBD patients taking antidepressants demonstrated significant abnormalities of 12/14 neurodegenerative markers tested, including olfaction (P = 0.007), color vision (P = 0.004), Unified Parkinson Disease Rating Scale II and III (P < 0.001 and 0.007), timed up-and-go (P = 0.003), alternate tap test (P = 0.002), Purdue Pegboard (P = 0.007), systolic blood pressure drop (P = 0.029), erectile dysfunction (P = 0.002), constipation (P = 0.003), depression indices (P < 0.001), and prevalence of mild cognitive impairment (13% vs. 60%, P < 0.001). All these abnormalities were indistinguishable in severity from RBD patients not taking antidepressants. However, on prospective follow-up, RBD patients taking antidepressants had a lower risk of developing neurodegenerative disease than those without antidepressant use (5-year risk = 22% vs. 59%, RR = 0.22, 95%CI = 0.06, 0.74).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although patients with antidepressant-associated RBD have a lower risk of neurodegeneration than patients with "purely-idiopathic" RBD, markers of prodromal neurodegeneration are still clearly present. Development of RBD with antidepressants can be an early signal of an underlying neurodegenerative disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Postuma</LastName><ForeName>Ronald B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Department of Neurology, McGill University, Montreal General Hospital, Montreal, Québec, Canada ; Centre d'Études Avancées en Médecine du Sommeil, Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gagnon</LastName><ForeName>Jean-Francois</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Tuineaig</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bertrand</LastName><ForeName>Josie-Anne</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Latreille</LastName><ForeName>Veronique</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Desjardins</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Montplaisir</LastName><ForeName>Jacques Y</ForeName><Initials>JY</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sleep</MedlineTA><NlmUniqueID>7809084</NlmUniqueID><ISSNLinking>0161-8105</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2000 Sep;15(5):843-9</RefSource><PMID Version="1">11009189</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sleep Med. 2013 Aug;14(8):744-8</RefSource><PMID Version="1">23347909</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2001 Aug 14;57(3):456-62</RefSource><PMID Version="1">11502913</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sleep. 2002 Mar 15;25(2):120-38</RefSource><PMID Version="1">11902423</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Ophthalmol. 2002 Dec;86(12):1408-11</RefSource><PMID Version="1">12446376</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2003 Jun;18(6):646-51</RefSource><PMID Version="1">12784267</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sleep. 2004 Mar 15;27(2):317-21</RefSource><PMID Version="1">15124729</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Psychiatry. 1988 May;145(5):652</RefSource><PMID Version="1">3358475</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Geriatr Soc. 1991 Feb;39(2):142-8</RefSource><PMID Version="1">1991946</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sleep. 1992 Jun;15(3):226-35</RefSource><PMID Version="1">1621023</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Disabil Rehabil. 1995 Jul;17(5):217-24</RefSource><PMID Version="1">7626768</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1996 Feb;46(2):388-93</RefSource><PMID Version="1">8614500</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Laryngoscope. 1996 Mar;106(3 Pt 1):353-6</RefSource><PMID Version="1">8614203</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Psychiatry. 1997 Aug;58(8):369-76; quiz 377</RefSource><PMID Version="1">9515980</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2004 Dec;19(12):1391-402</RefSource><PMID Version="1">15452868</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2004 Dec 9;351(24):2498-508</RefSource><PMID Version="1">15590952</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2005 Dec 27;65(12):1863-72</RefSource><PMID Version="1">16237129</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2006 Mar 28;66(6):845-51</RefSource><PMID Version="1">16567700</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2006 Jul;5(7):572-7</RefSource><PMID Version="1">16781987</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2012 Jan;71(1):49-56</RefSource><PMID Version="1">22275251</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sleep Med. 2012 Feb;13(2):211</RefSource><PMID Version="1">22137105</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2012 Apr;83(4):470-2</RefSource><PMID Version="1">22250185</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2012 Apr 15;27(5):617-26</RefSource><PMID Version="1">22508280</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2012 Jun;135(Pt 6):1860-70</RefSource><PMID Version="1">22561644</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2012 Dec;27(14):1781-8</RefSource><PMID Version="1">23147270</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2006 Sep 12;67(5):742-7</RefSource><PMID Version="1">16966533</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Aug 15;22(11):1581-6</RefSource><PMID Version="1">17523195</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Nov 15;22(15):2249-55</RefSource><PMID Version="1">17876851</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Dec;22(16):2314-24</RefSource><PMID Version="1">18098298</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2008 Apr 8;70(15):1250-7</RefSource><PMID Version="1">18216303</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sleep Med. 2009 Jan;10(1):60-5</RefSource><PMID Version="1">18226952</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Psychiatry. 2008 Sep;69(9):1374-82</RefSource><PMID Version="1">19193338</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2009 Apr 14;72(15):1296-300</RefSource><PMID Version="1">19109537</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2009 Jun;80(6):671-4</RefSource><PMID Version="1">19448091</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2009 Jul;66(1):39-47</RefSource><PMID Version="1">19670440</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2009 Nov 24;73(21):1752-8</RefSource><PMID Version="1">19933976</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2009 Nov 15;24(15):2225-32</RefSource><PMID Version="1">19768814</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sleep Med. 2010 Feb;11(2):167-71</RefSource><PMID Version="1">20022299</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Psychiatry. 2010 Aug;71(8):1101-3</RefSource><PMID Version="1">20797385</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2010 Sep;81(9):1008-13</RefSource><PMID Version="1">20562452</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2010 Oct 15;25(13):2044-51</RefSource><PMID Version="1">20818653</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sleep Med. 2011 Mar;12(3):278-83</RefSource><PMID Version="1">21317035</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2011 May;69(5):811-8</RefSource><PMID Version="1">21246603</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Neurol. 2011 Jun;7(6):323-31</RefSource><PMID Version="1">21537355</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sleep Med. 2013 Aug;14(8):788-94</RefSource><PMID Version="1">22841026</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2001 Jul;50(1):34-41</RefSource><PMID Version="1">11456307</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003118" MajorTopicYN="N">Color Perception</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="N">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020187" MajorTopicYN="N">REM Sleep Behavior Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012903" MajorTopicYN="N">Smell</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC3792373</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson disease</Keyword><Keyword MajorTopicYN="N">REM sleep behavior disorder</Keyword><Keyword MajorTopicYN="N">antidepressants</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24179289</ArticleId><ArticleId IdType="doi">10.5665/sleep.3102</ArticleId><ArticleId IdType="pmc">PMC3792373</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000848 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000848 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24179289
|texte= Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24179289" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |